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Background: Low grade chronic inflammation is observed in patients with type 2 diabetes mellitus (T2DM).
Endotoxin derived from gut bacteria may act as a potent inflammatory stimulant. Probiotics, which are believed to
contain health promoting live microorganisms, may influence circulating endotoxin levels. Ingestion of live
probiotic cultures may alter gut microbiota in a beneficial manner to reduce inflammation; no information is
available whether or not they do so in patients with T2DM. Therefore, the aim of this study is to characterize the
beneficial effects of probiotics on circulating endotoxin levels and other biomarkers related to systemic low-grade
inflammation in patients with T2DM.
Methods: One hundred and twenty consenting adult Saudi T2DM patients (naïve or newly diagnosed and without
co-morbidities) will be enrolled in this clinical trial and randomized to receive daily placebo or probiotics
(Ecologic®Barrier) for 26 weeks in a double-blind manner. Inflammatory and metabolic markers will be measured
and fecal samples analyzed. Measurements/samples will be obtained at baseline and after 4, 8, 12/13 and 26 weeks
of treatment.
Discussion: It is expected that the probiotic product will induce beneficial changes in gut microbiota, reduce the
systemic inflammatory state through altering systemic endotoxin levels and, as such, reduce the systemic
inflammatory response observed in T2DM subjects.
Trial registration: ClinicalTrials.gov Identifier: NCT01765517
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The human gastrointestinal tract contains bacteria, ar-
chaea and eukarya. In particular, bacteria living in the
gut achieve the highest cell density recorded for any eco-
system [1]. However, gut microbiota does not exist inde-
pendently and interacts at several levels in the functions
of the body [1]. Specifically, gut microbiota can influence
intestinal peristalsis [2], but also affects the expression
of various host genes that regulate nutrient uptake,
metabolism, angiogenesis, mucosal barrier function, the* Correspondence: msa85@yahoo.co.uk
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reproduction in any medium, provided the ordevelopment of the enteric nervous system and matur-
ation of mucosal immunity [3]. Interestingly it appears
that fragments of Gram negative bacteria derived from
the gut (endotoxin) can cross the intestinal mucosa to
enter the circulation, and may represent an important
mediator of low-grade systemic inflammation influenced
by the host's own gut microbiota and metabolic state.
Previous studies have shown that low levels of endotoxin
can enter the blood circulatory system, which may
stimulate an innate immune response from adipose
tissue, liver and skeletal muscle, leading to production of
pro-inflammatory cytokines [4-9]. Endotoxin has been
shown to act as a mediator of inflammation in liver dis-
ease [10,11], whilst cross-sectional and longitudinal
studies have indicated that a reduction in circulatingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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kines and inflammatory response [12-15]. Further-
more, abnormal alterations in diet have a profound
influence on human endotoxin circulation, but more
so for patients with type 2 diabetes mellitus (T2DM)
[16]. It makes sense that manipulation of diet to
normalize the gut microflora and metabolic functions
has been the mainstay management for most chronic
diseases. In fact, a well-controlled diet is a major non-
pharmacologic option for the prevention of T2DM
[17,18]. As such, influencing the gut microbiota with
the addition of probiotics may affect the systemic ef-
fects of endotoxin and represent a new and enhanced
mechanism to treat low-grade chronic inflammatory
conditions, such as seen in T2DM. The present study
proposes to test the hypothesis that probiotics will
alter the gut microbiota sufficiently to reduce systemic
endotoxins and the resulting inflammation in subjects
with T2DM, thus offering an additional intervention to
treat these patients. To achieve this, 120 consenting
adult Saudi T2DM patients without co-morbidities will
be enrolled in this clinical trial and randomized to
receive twice-daily placebo or probiotics for 26 weeks
in a double-blind manner. Glycemic and inflammatory
markers will be measured at baseline and at weeks 8,
12 and 26. The study will specifically explore the ef-
fects of probiotics on endotoxin levels in patients with




In this 26-week, single-center, double-blind, randomized,
placebo-controlled study, 60 patients with T2DM will be
treated with probiotics and 60 will be treated with pla-
cebo. Interventions will be performed at weeks 0, 4, 8, 12
and 26 in all subjects. Patients allocated to the probiotics
group will receive two sachets with 2 g freeze-dried
powder of the probiotic mixture Ecologic®Barrier daily
(Winclove probiotics, the Netherlands). Ecologic®Barrier
(2.5 × 109 cfu/gram) contains the following bacterial
strains: Bifidobacterium bifidum W23, Bifidobacterium
lactis W52, Lactobacillus acidophilus W37, Lactobacil-
lus brevis W63, Lactobacillus casei W56, Lactobacillus
salivarius W24, Lactococcus lactis W19 and Lactococcus
lactis W58. Participants in the placebo group will receive
the placebo consisting of the carrier of the probiotic prod-
uct, that is maize starch and maltodextrins. The placebo is
indistinguishable in color, smell and taste from the probiotic
sachets, but contains no bacteria.
Recruitment of patients
Recruitment of patients to this study will be made
possible by collaboration with primary care centersthroughout Riyadh and the Biomarkers Research Pro-
gram, College of Science, King Saud University.
Ethical approval
The study protocol has been approved by the ethics
committee of the College of Science, King Saud Uni-
versity, Riyadh, Saudi Arabia.
Inclusion criteria
 Stable and well controlled T2DM (glycosylated
hemoglobin (HbA1c) < 7.5% and no change in oral
anti-diabetic medications during the last 6 months)
 Age 20 to 75 years
 Provision of written informed consent
Exclusion criteria
 Chronic gastrointestinal disease (except irritable
bowel syndrome)
 Systemic antibiotics within 6 weeks before inclusion
 Use of probiotics within 3 months before inclusion
 Regular intake of insulin or insulin analogs,
antibiotics or probiotics, antacids, H2-receptor
blockers, proton pump inhibitors, loperamide,
cholestryramine, ω3-unsaturated fatty acid
supplements, fibrates, corticosteroids or sex
steroids
 Daily alcohol consumption > 30 g
 Significant immunodeficiency
 Known cardiac valvular disease
 Breast-feeding or pregnancy
 Non-Arab ethnicity
 Participation in another clinical trial within the
last 6 months
 Legal incapability or mental incapacity to give
consent.
Allocation to treatment
After confirmation of eligibility and obtaining written
informed consent, the patients will be given a unique
subject number by the research nurse. The randomization
(stratified for gender) will be performed by the probiotic
company and the patients and clinicians at the pri-
mary care center will be blinded to the treatment
received. The eligible patients will be allocated
(1:1) to treatment for 26 weeks with either the
probiotics supplement or placebo. Subjects will be
instructed to:
 Ingest one sachet before breakfast and one sachet
before going to bed, by mixing the powder in
lukewarm water and drinking it.
 The sachets will be stored at room temperature.
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Case report forms (CRF) will be used to record data for
all participants, and will be completed by the research
nurse, who will also enter the data into an electronic
database.
Study schedule and location
After inclusion, all further treatments will be managed
at the primary care center where the subject was
recruited (see Table 1 for scheduled visits). A research
nurse and a research dietician will be responsible for
all contacts with patients. Doctors associated with the
research team will be available if problems arise.
Acquisition of clinical data and assessment of compliance
 Medical history, including the presence of chronic
diseases, regular medication, smoking and alcohol
habits, will be recorded before inclusion.
 Nutritional habits will be assessed using a
standardized 14-day recall questionnaire, which will
be discussed with a dietician.
 Changes in medication during the study period will
be recorded
 Anthropometric measurements will be made using
standardized methods. Height will be measured at
the start of treatment. Weight (in light clothing
without shoes or items in pockets), waist
circumference (measured as a horizontal plane at
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X X X X(measured as a horizontal plane at the level of the
trochanter major) will be measured at the start and
end of the treatment.
 Liver ultrasonography will be performed either at
screening or at the start of treatment to determine
the presence or absence of a bright liver indicative
of steatosis. Patients with fatty liver and liver
transaminases >1.5 × the upper limit of normal will
be offered referral to a hepatologist.
 Compliance will be monitored at weeks 4, 8, 12 and
26. Patients will bring their previously received
sachets to the primary care center to calculate the
mean number of sachets used per day.
Acquisition of routine biochemical data and biological
samples
 Blood samples obtained will be analyzed at the
Biomarkers Research Program to measure glucose,
HbA1c, insulin, C-peptide, total cholesterol, high-
density lipoprotein cholesterol, low-density
lipoprotein cholesterol, triglycerides, alanine
aminotransferase and aspartate aminotransferase
levels.
 Fasting blood samples will be collected at weeks 0, 8
and 26. Peripheral venous blood will be drawn into
pyrogen-free tubes without any anticoagulant. The
tubes will be immediately placed in ice, allowed to
coagulate, and centrifuged (2500 ×g for 10 minutes
at 4°C) within 2 hours of collection. Serum samples
will be stored at −80°C until use. At least two 2-mL
serum samples will be collected at each time-point.
 Stool samples will be obtained at the same time
points as blood samples and stored in a plastic
sealable bag to be handed over to the clinic. Once at
the clinic, the samples will be divided, flash frozen,
and stored at −80°C. Changes in gut microbiota will
be profiled using signature-tagged sequencing
(pyrosequencing) of amplified 16S rRNA genes
followed by automated bioinformatics analysis.
Targeted RT-PCR will also be used to examine
bacterial species such as Enterobacteria and
Bifdobacteria relative to the universal bacterial
primer set. Pyrosequencing and RT-PCR will be
performed in a sub-cohort (n = 15) of patients
considering the final systemic findings. Samples will
be retained for subsequent studies.
Subject withdrawal
Subjects may withdraw from the trial at any time at their
own request, or they may be withdrawn at any time at
the discretion of the investigator for safety, behavioral or
administrative reasons. The subjects will also be with-
drawn from the study in case of:
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week during weeks 0 to 22
 Any use of systemic antibiotics during weeks 22 to 26
Patient safety
Adverse events
Adverse events are undesirable signs or symptoms that
occur during the study and may or may not be causally
related to the treatment. All adverse events considered
possibly, probably or definitely related to the tested
product will be recorded on CRFs.
Serious adverse events
Serious adverse events are defined as events that are
fatal, life-threatening, disabling, incapacitating or result
in hospitalization or prolonged hospital stay, or result
in malformation. All will be recorded in the CRF,
whether they are related to the test product or not.
According to previous studies [9], probiotics are safe,
and any serious adverse event that might be possibly,
probably or definitely related to the test product will be
regarded as unexpected. All unexpected serious adverse
events will be reported immediately to the Medicines
and Healthcare products Regulatory Agency. Any ser-
ious adverse event that might be related to the tested
product will immediately lead to discontinuation of the
test product.
Ethical and regulatory aspects
The study will be performed in accordance with the
protocol and the ethical principles that have their ori-
gin in the Declaration of Helsinki as well as with the
International Council for Harmonization Guidance on
Good Clinical Practice. These documents state that
the informed consent of subjects is an essential pre-
condition for participation in the clinical study. The
study will commence only after obtaining approval
from the local ethical review board of the College of
Medicine Research Center, King Saud University.
Statistical aspects
Sample size
Preliminary data indicate that serum endotoxin levels
in T2DM patients are two to three times higher than
in control subjects. We hypothesize that treatment
with probiotics will reduce mean endotoxin levels
by 25 to 30%, while no change will be seen in
the placebo group. To obtain 80% power to demon-
strate a statistically significant difference (two-sided
P-value = 0.05) between the two treatments, 100
patients must be treated (50 patients per group). As
we expect a dropout rate of 15%, we will include 120
patients in the study.The sample size was calculated based on the esti-
mated mean change during treatment (Δ-values) and
corresponding standard deviation (SD) of the change.
Since we have no repeated measurements of endo-
toxin in the same individuals, we need to estimate
the SD for the change. Assuming that the correlation
between 1 and 2 yields a measurement of 0.70, the
SD for the Δ-value is 78% of the SD of separate mea-
surements (Table 2). Table 3 shows the estimated
sample size according to various assumptions of treat-
ment effect and correlation between one and two
measurements.
Plan for data analysis
As this trial is designed to assess the physiological effects
rather than support clinical indications for treatment
with probiotics in T2DM, we plan to perform per proto-
col analyses. Only subjects treated with at least 80% of
the planned doses for at least 80% of the time will be
considered as treated per protocol.
Raw data will be entered into statistical software
(SPSS version 16.5, Chicago, IL, USA). Preparation of
the dataset will be done prior to analysis. Descriptive
statistics will be performed, and frequencies will be
presented as a percentage. Continuous variables will
be presented as mean ± SD. Variables exhibiting non-
Gaussian variables will be transformed prior to ana-
lysis. Repeated measures analysis of co-variance will
be used to compare groups, which will represent a
combination of analysis of variance and linear regres-
sion. Confounding and fixed variables such as age
and gender, as well as body mass index, will be taken
if proper matching has not been achieved prior to re-
peated measures. Post hoc Banjamini-Hohberg correc-
tions will be done for multiple comparisons. For
comparison of two groups, an independent t-test will
be applied for continuous variables and Mann–Whitney
for non-continuous variables. Analysis of adverse events
(if any) will be performed using Chi-Square test and
Fisher’s exact test following assumptions of randomness,
independence and size. Significance will be set at P <
0.05.
Limitations
The investigators are aware that systemic inflammatory
markers may not change during the clinical trial; how-
ever, this would not preclude the study as we understand
that probiotics do affect gut microbiota and that this
may have beneficial effects as noted in previous rodent
and human studies. Furthermore, probiotics have been
previously shown to affect lipopolysaccharide levels and
this may still have long-term beneficial effects which
may have a trend effect on inflammatory or insulin re-
sistance markers and thus may indicate that a longer
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the effects of a probiotic in a clearly designed clinical
trial will provide new understanding and warrants
investigation.
Discussion
Many different probiotic strains have been identified and
the effects of these bacteria, either given in monoculture
or as a cocktail of various strains, have been subject to
increasing scientific evaluation in recent years. Probiotic
bacteria (with the best documented strains being species
of Lactobacillus or Bifidobacterium) inhibit the growth
of pathogenic bacteria by acidifying the gut lumen,Table 3 Sample size determination for endotoxin





























Δ-value, mean change; SD, standard deviation.competing for nutrients, and producing antimicrobial
substances [19,20]. Furthermore, they adhere to the
gastrointestinal mucosa and are thought to prevent bac-
terial translocation from the gut [21]. The strongest evi-
dence for the use of probiotics has been in the
management of diarrhea [22]. Data extrapolated from
a large number of studies, including systemic reviews
[23-26], meta-analyses [27-30], open-label studies [31,32]
and multicenter trials testing the efficacy of probiotics
in preventing diarrhea, concluded that, in addition to
having a good safety profile, probiotics significantly re-
duced the duration and frequency of acute diarrhea
[33]. In addition, trials have documented favorable ef-
fects of probiotics in other gastrointestinal diseases
(for example, irritable bowel syndrome, pouchitis and
necrotizing enterocolitis in premature infants). Studies
in obesity have also shown altered gut microbial com-
positions in human subjects and in mice [34-43]. The
guts of obese human subjects appear to have reduced
numbers of Bacteroidetes and increased numbers of
Firmicutes compared with lean people [36]. During a
1-year intervention trial in obese humans on a hypocaloric
diet, an increased proportion of fecal Bacteroidetes was
observed to parallel weight loss [36]. Diet-induced obesity
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versible with dietary manipulation aimed at limiting
weight gain [37]. The finding that the microbial compos-
ition is modulated by dietary modification suggests that
differences in the gut composition between obese and lean
individuals are related to dietary factors independent of
obesity [15,44]. However, not all studies have shown bene-
ficial effects of probiotics, and thus caution should be
taken in terms of the dosage and strains to be used, as
these may have important ramifications on the effects ob-
served. In this study, a combination of probiotic strains
will be used, as there are suggestions that multispecies
products are more effective than single strain products
[45,46]. The strains were selected for this product based
on different in vitro screening criteria. Among the criteria
were the inhibition of cytokine-induced barrier dysfunc-
tion of the epithelial cell line Caco-2, the capacity to in-
duce expression of interleukin-10 [47] (as this anti-
inflammatory cytokine has a protective function on the
epithelial barrier [48]), the ability to break down lipopoly-
saccharides and the inhibition of mast cell activation [49].
Taken together, the current evidence appears to sup-
port a role for the gut microbiota in the pathogenesis of
diet-induced obesity and related metabolic disorders,
which may be reversible with dietary and/or gut micro-
biota manipulation [50]. As the gut microbiota is the
main source of endotoxin, treatment with probiotics
may influence the circulating levels of endotoxin by al-
tering the microbiota composition. To date, relatively
few studies have examined the effects of endotoxin in
metabolic diseases using probiotics. To the best of our
knowledge, this hypothesis has not been tested except in
a small study of patients with cirrhosis in which a 25%
reduction in endotoxin was reported [1]. However, ani-
mal studies have revealed that treatment with probiotics
may be beneficial in insulin-resistant states [2,37].
Probiotics also delay the onset of glucose intolerance in
high-fructose-fed rats [3]. To expand on these earlier
findings, the present study will explore the potential
beneficial effects of probiotics on circulating endotoxin
levels and other markers for systemic low-grade inflam-
mation in patients with T2DM.
In summary, we expect that our findings will demon-
strate that probiotics alter gut microbiota in T2DM and
that, in theory, the alterations will be metabolically fa-
vorable with continued probiotic use. Since the efficacy
of probiotics is directly linked to the type of strain, we
will also be able to identify which strains used in the
intervention are most beneficial for patients with T2DM.
Further investigations, however, will be needed whether
the efficacy of the probiotics used in this study can be
extended to prevention levels. Regardless, our study will
be the first to address this issue beyond classical inflam-
matory conditions. This will have a fundamental impacton how we should treat the inflammatory component of
T2DM, particularly once the results are verified in a lar-
ger cohort of patients.
Trial status
Estimated enrollment: 120
Study start date: October 2013
Estimated study completion date: October 2015
Estimated primary completion date: October 2015
Abbreviations
CRF: case report form; HbA1c: glycosylated hemoglobin; RT-PCR: reverse
transcription polymerase chain reaction; SD: standard deviation; T2DM: type
2 diabetes mellitus.
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